Madrigal Mental Care
Nano particles psychedelics in intranasal delivery for mental health conditions
Company Overview
Snapshot
Founded in September 2021 by David Gabay, Madrigal Mental Care operates with 1–10 employees. The company is focused on developing treatments for mental health conditions using nanotechnology, with its Nanovo intranasal spray designed for rapid and efficient delivery of psychedelic substances. In March 2024, Madrigal announced groundbreaking ketamine research for PTSD treatment and upcoming in-human clinical trials.
Business overview
Madrigal Mental Care is a biopharmaceutical company leveraging nanotechnology to develop treatments for mental health conditions, including post-traumatic stress disorder (PTSD). The company's core technology involves a Nanovo intranasal spray that delivers nanoencapsulated psychedelic drugs, such as psilocybin, ketamine, mescaline, and MDMA, directly to the brain. This approach aims to fundamentally alter brain coding rather than just treating symptoms, offering a transformative solution with minimal side effects. Madrigal operates within the Health Tech & Life Sciences sector, specifically focusing on drug delivery, pharmaceuticals, and biotechnology.
Strategic signal
In March 2024, Madrigal Mental Care announced groundbreaking ketamine research for PTSD treatment, coupled with plans for upcoming in-human clinical trials. This development signals a significant advancement in the company's product pipeline and a potential validation of its nanotechnology-based drug delivery system for mental health applications. For investors, this indicates a move towards clinical validation and potential market entry for a novel therapeutic approach to PTSD.
Log in to access full profile ›Company Intelligence Q&A
- What is Madrigal Mental Care's primary focus?
- Madrigal Mental Care focuses on using nanotechnology for the intranasal delivery of psychedelic drugs to treat mental health conditions, such as post-traumatic stress disorder (PTSD).
- What is the Nanovo intranasal spray?
- The Nanovo intranasal spray is Madrigal Mental Care's proprietary technology designed to deliver active, nanoencapsulated psychedelic substances directly to the brain for rapid, safe, and efficient uptake.
- When was Madrigal Mental Care founded?
- Madrigal Mental Care was founded in September 2021.
- What significant research did Madrigal Mental Care announce in March 2024?
- In March 2024, Madrigal Mental Care announced groundbreaking ketamine research for PTSD treatment and plans for upcoming in-human clinical trials.
- What types of psychedelic drugs does Madrigal Mental Care utilize in its treatments?
- Madrigal Mental Care utilizes molecules composed of psychedelic drugs such as psilocybin, ketamine, mescaline, and MDMA.